Eliminating hepatitis C infection in Australia through harm reduction, education and treatment scale up
Hepatitis C affects over 230,000 people in Australia. Currently only 1 to 2 per cent of people with chronic HCV are treated annually. In 2016, the World Health Organization set targets to reduce new HCV infections by 80 per cent, reduce deaths due to HCV by 65 per cent, and eliminate HCV as a public health problem by 2030.
With new, effective non-interferon-based treatments, it should be possible for Australia to achieve these elimination targets. Key to our success in reducing HCV-related deaths and new infections in Australia will be the upscaling of treatment for all people with chronic HCV infection, including those currently transmitting HCV who are chiefly people who inject drugs. New community-based treatment programs in primary care, drug and alcohol services and community organisations are being rolled out locally.
This project is open to students
Improve the quality of care
The project will aim to explore:
- improved harm reduction strategies
- workforce development and health service delivery
- supports needed for prescribers to start treatment.
The outcomes will help facilitate treatment uptake and improve the quality of care.
Open to
- Honours
- Masters by research
- PhD
Supervisors
Contact
Project contacts
Professor Joseph (Joe) Doyle
Deputy Program Director, Disease Elimination; Co-Head, Infectious Diseases Clinical Research; President, Hepatitis Australia; NHMRC Clinical Research Fellow
Project team
Professor Joseph (Joe) Doyle
Deputy Program Director, Disease Elimination; Co-Head, Infectious Diseases Clinical Research; President, Hepatitis Australia; NHMRC Clinical Research Fellow
More student projects
View 62 more
Young people’s health in Australia: statistics from the Sex, Drugs and Rock ‘n’ Roll survey
Every year, we survey young people about their sexual health, drug use, mental health and wellbeing. That data informs public health policies and programs.
Germinal centre organoids to investigate human immune response to infection and vaccination
We're using germinal centre organoid models to investigate human immune development to malaria parasites and malaria vaccines.
Impact of malaria and other host factors on COVID-19 immune responses following infection and vaccination
Understanding immune development to the COVID-19 virus (SARS-CoV-2) in areas of high malaria transmission will inform future COVID-19 control strategies and underlying immune development.
Why study at Burnet?
When you study at Burnet, you broaden your impact working across our three Institute-wide programs: Disease Elimination; Health Security and Pandemic Preparedness; Maternal, Child and Adolescent Health.
Train with internationally recognised experts in a structured student support system, and gain a holistic research experience along the way.